be_ixf;ym_201908 d_24; ct_50 Skip to content

Asbestos-Related Disease

Represented thousands of asbestos victims throughout the United States

You may have a claim

Leaders in Securities Fraud Litigation

Protecting U.S. and foreign plaintiffs

Learn More

Leading Complex Legal Battles

From opioid litigation and dangerous Takata airbags, to securities fraud, asbestos, and medical drugs and devices

Learn More

Current Cases

See All Cases
Active Case

Hernia Mesh Lawsuit

Hernias are a problem that for many requires surgery to alleviate daily pain, discomfort and other symptoms. Unfortunately, some who were promised a solution by having hernia mesh implanted to repair the hernia instead found themselves facing potential problems.

More Information

Attorneys:

Jonathan D. Orent Donald A. Migliori

Headlines

See All Headlines

June 25, 2019

Two Motley Rice lawyers promoted to members

We are pleased to announce that two associates have been promoted to member attorneys. The attorneys selected have experience working in the firm’s various practice areas, including securities fraud, antitrust litigation, consumer fraud, and representing victims of mesothelioma and asbestos exposure.

Read More

June 4, 2019

SEC awards two financial industry whistleblowers $3 million

The Securities and Exchange Commission announced an award of $3 million to a pair of whistleblowers who provided original information to the Commission that led to a successful enforcement action involving an alleged securities violation that harmed retail investors.

Read More

June 3, 2019

Milwaukee jury awards $6 million damages to lead poisoned young men

A Milwaukee, Wis., jury has found lead pigment manufacturers The Sherwin-Williams Co., E.I. DuPont de Nemours & Co., and Armstrong Containers, Inc., responsible for the toxic lead exposures of three young men, all residents of Milwaukee and minors at the time of their lead exposure in their homes. The jury awarded $6 million total, $2 million to each plaintiff.

Read More

Recent Blog Posts

See All Posts
Homepage | Motley Rice

August 19, 2019

FDA’s push for transparency long overdue

by: Fidelma L. Fitzpatrick

Generally speaking, manufacturers are required to submit individual reports to the FDA for each patient who sustains an injury or complication caused by a medical product. Established in 1997, Alternative Summary Reporting Program allowed manufacturers to bypass that standard by submitting quarterly summaries for cases that involve “well-known” complications. The FDA claims that this policy allowed the agency to “more efficiently review reports of well-known, well-understood adverse events.” However, the public was largely kept in the dark because this massive database was kept hidden, available only to the FDA – until now.

Read More